Global Epoprostenol Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3200/- USD | Published Date: April 14, 2021 |

The global epoprostenol market size is accounted to grow at a significant CAGR of 3% during the forecast period from 2021 to 2027 and expected to reach at USD 2,286.3 million by 2027. The growing incidence of pulmonary arterial hypertension worldwide primarily drives the epoprostenol market growth. Additionally, rising public health awareness and effective implementation of treatment guidelines regarding the treatment of primary pulmonary hypertension will further consolidify the epoprostenol market growth.

Epoprostenol is enzymatically biosynthesized form the prostaglandin endoperoxides in human vascular tissue as a sodium salt. It possesses potent vasodilator effects, it belongs to the family of prostacyclin (PG12) class which activates the G protein coupled receptors and endothelial cells present in the human body, which further activates Cyclic AMP to inhibit platelet aggregation. It is available as an injectable, powder for reconstitution in vials of dose strengths of 0.5mg/vial and 1.5mg/vial. Epoprostenol needs to be taken under medical supervision to prevent the occurrence of drug-related severe adverse events.

Market Segment Insights:

Primary pulmonary hypertension is representing the largest market share in the clinical application segment for the epoprostenol market. Effective implementation of treatment guidelines pertaining to the treatment of primary pulmonary hypertension and increasing public health awareness regarding the therapeutic efficacy of epoprostenol in its treatment together fortify the market growth. It is further subdivided into heritable pulmonary arterial hypertension (HPAH), idiopathic pulmonary arterial hypertension (IPAH), associated pulmonary arterial hypertension (APAH), etc. It is predicted that during the forecast period that patients suffering from NYHA Functional Class III-IV symptoms will be on a rise, hence clinical trial investigation regarding the therapeutic efficacy and safety of epoprostenol in resolving the symptoms will be progressively conducted.

Epoprostenol Market Size and Growth

To know more about the study, request a report sample

Hospital pharmacy is presently leading the distribution channel segment for the epoprostenol market. The dose posology varies as per the category of patients i.e. pediatric and adult, hence precise compounding by hospital pharmacists is mandatory to prevent the occurrence of severe drug-related adverse events. Retail pharmacy is expected to register comfortable market growth in the near future owing to the flourishing generic drugs market in the developing regions and its ability to provide medication at a lower price to patients residing in remote locations.

The epoprostenol comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2020 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The epoprostenol market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

  • 2018-19 – Historical Year
  • 2020 – Base Year
  • 2021-2027 – Forecast Period

Global Epoprostenol Market Segmentation:

By Clinical Application:

  • Primary Pulmonary Hypertension
  • NYHA Functional Class III-IV Symptoms

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographic Coverage:

North America is the supreme leader in the geography segment for the epoprostenol market. The growing incidence of primary pulmonary hypertension primarily drives the epoprostenol market growth in the region. As per the latest information provided by the Center for Disease Control and Prevention (CDC), the prevalence rate of primary pulmonary hypertension is 2 cases per million Americans. Additionally, the presence of developed healthcare infrastructure and affordable reimbursement scenarios further propel the market growth in the region. Europe is the second-largest regional segment for the epoprostenol market. Strategic collaboration between academic research institute and pharmaceutical giants in understanding the therapeutic efficacy of epoprostenol in resolving NYHA Functional Class III-IV symptoms in patients consolidates the market growth in the region. The Asia Pacific is anticipated to be the fastest growing regional segment during the forecast period owing to the flourishing generic drugs market and effective implementation of treatment guidelines pertaining to the treatment of pulmonary hypertension in the region.

Market Competition Assessment:

Key players operating in the global epoprostenol market are Actelion (Johnson & Johnson), Merck & Co., Inc., Sandoz, Inc., GlaxoSmithKline, Plc., and Mayne Pharma. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

List of Key Companies:

  • Actelion (Johnson & Johnson)
  • Merck & Co., Inc.
  • ROTEXMEDICA
  • GlaxoSmithKline, Plc.
  • Sandoz, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Gebro Pharma GmbH
  • Mayne Pharma
  • Campus Pharma AB

Key Questions Answered by Epoprostenol Market Report:

  • Global epoprostenol market forecasts from 2021-2027
  • Regional epoprostenol market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
  • Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
  • Epoprostenol submarket forecasts from 2021-2027 covering the market by clinical application, by distribution channel, and geography
  • Various industry models such as SWOT analysis, Value Chain Analysis pertaining to epoprostenol market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level epoprostenol markets from 2021-2027
  • Competitive Landscape and market positioning of top 10 players operating in the epoprostenol market
Table of Content:

Chapter 1. Introduction


1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Market Segmentation
1.3.2. Years Considered for the Study
1.4. Currency
1.5. Limitation
1.6. Market Stakeholders

 

Chapter 2. Research Methodology


2.1. Market Size Estimation
2.2. Market Breakdown and Data Triangulation
2.3. Market Share Estimation
2.4. Key Data From Secondary Sources
2.5. Key Data From Primary Sources
2.6. Key Industry Insights
2.7. Assumptions for the Study

 

Chapter 3. Executive Summary


3.1. Global Epoprostenol Market Snapshot
3.2. Global Epoprostenol Market, by Clinical Application, 2020 (US$ Mn)
3.3. Global Epoprostenol Market, By Distribution Channel, 2020 (US$ Mn)
3.4. Global Epoprostenol Market, by Geography, 2020 (US$ Mn)

 

Chapter 4. Epoprostenol Market: Dynamics and Future Outlook


4.1. Market Overview
4.2. Drivers
4.3. Challenges
4.4. Opportunities
4.5. Attractive Investment Proposition, by Geography, 2020

 

Chapter 5. Global Epoprostenol Market, by Clinical Application


5.1. Introduction
5.2. Primary Pulmonary Hypertension
5.3. NYHA Functional Class III-IV Symptoms

 

Chapter 6. Global Epoprostenol Market, By Distribution Channel


6.1. Introduction
6.2. Hospital Pharmacy
6.3. Retail Pharmacy
6.4. Others

 

Chapter 7. Global Epoprostenol Market, by Geography


7.1. Introduction
7.1. North America Epoprostenol Market Analysis, 2017 – 2027
7.1.1. North America Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
7.1.2. North America Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.1.3. North America Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe Epoprostenol Market Analysis, 2017 – 2027
7.2.1. Europe Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
7.2.2. Europe Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.2.3. Europe Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
7.2.3.1. U.K.
7.2.3.2. Germany
7.2.3.3. Russia
7.2.3.4. France
7.2.3.5. Italy
7.2.3.6. Spain
7.2.3.7. Ukraine
7.2.3.8. Rest of Europe
7.3. Asia Pacific Epoprostenol Market Analysis, 2017 – 2027
7.3.1. Asia Pacific Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
7.3.2. Asia Pacific Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.3.3. Asia Pacific Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
7.3.3.1. China
7.3.3.2. Japan
7.3.3.3. Rest of Asia Pacific
7.4. Latin America Epoprostenol Market Analysis, 2017 – 2027
7.4.1. Latin America Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
7.4.2. Latin America Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.4.3. Latin America Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
7.4.3.1. Brazil
7.4.3.2. Mexico
7.4.3.3. Rest of Latin America
7.5. Middle East and Africa Epoprostenol Market Analysis, 2017 – 2027
7.5.1. MEA Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
7.5.2. MEA Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
7.5.3. MEA Epoprostenol Market, by Country/Region, 2017 – 2027 (US$ Mn)
7.5.3.1. GCC
7.5.3.2. Rest of MEA

 

Chapter 8. Company Profiles


8.1. Actelion (Johnson & Johnson)
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Recent Developments
8.1.5. SWOT Analysis
8.2. Merck & Co., Inc.
8.3. ROTEXMEDICA
8.4. GlaxoSmithKline, Plc.
8.5. Sandoz, Inc.
8.6. Teva Pharmaceutical Industries Ltd.
8.7. Bayer AG
8.8. Gebro Pharma GmbH
8.9. Mayne Pharma
8.10. Campus Pharma AB

To know more about the study, request a report sample

List of Figures:

FIG. 1 Epoprostenol: Market Segmentation
FIG. 2 Global Epoprostenol Market, by Clinical Application, 2019 (US$ Mn)
FIG. 3 Global Epoprostenol Market, By Distribution Channel, 2019 (US$ Mn)
FIG. 4 Global Epoprostenol Market, by Geography, 2019 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2019
FIG. 6 Global Primary Pulmonary Hypertension Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 7 Global NYHA Functional Class III-IV Symptoms Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 8 Global Hospital Pharmacy Market for Epoprostenol, 2017 – 2027 (US$ Mn)
FIG. 9 Global Retail Pharmacy Market for Epoprostenol, 2017 – 2027 (US$ Mn)
FIG. 10 Global Other Distribution Channel Market for Epoprostenol, 2017 – 2027 (US$ Mn)
FIG. 11 U.S. Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 12 Canada Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 13 U.K. Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 14 Germany Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 15 Russia Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 16 France Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 17 Italy Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 18 Spain Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 19 Ukraine Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest of Europe Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 21 China Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 22 Japan Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest of Asia Pacific Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 24 Brazil Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 25 Mexico Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest of Latin America Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 27 GCC Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest of MEA Epoprostenol Market, 2017 – 2027 (US$ Mn)
FIG. 29 Epoprostenol Market: Research Methodology

To know more about the study, request a report sample

List of Tables:

TABLE 1 Global Epoprostenol Market Snapshot
TABLE 2 Global Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 3 Global Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 4 Global Epoprostenol Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 5 North America Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 6 North America Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 7 North America Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 8 Europe Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 9 Europe Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 10 Europe Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 11 Asia Pacific Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 12 Asia Pacific Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 13 Asia Pacific Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 14 Latin America Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 15 Latin America Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 16 Latin America Epoprostenol Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 17 Middle East and Africa Epoprostenol Market, by Clinical Application, 2017 – 2027 (US$ Mn)
TABLE 18 Middle East and Africa Epoprostenol Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
TABLE 19 Middle East and Africa Epoprostenol Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 20 Actelion (Johnson & Johnson).: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 22 ROTEXMEDICA: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 23 GlaxoSmithKline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 24 Sandoz, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 25 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 26 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 27 Gebro Pharma GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 28 Mayne Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
TABLE 29 Campus Pharma AB: Company Snapshot (Business Description; Financial Information; Product Portfolio; SWOT Analysis; Recent Developments)
Fill the given form to inquiry before buying for Epoprostenol Market Report

Your Designtaion (required):


(Additional country analysis and conmapny analysis will be added according to request, please read our FAQs below:)(Reports covers the COVID-19 impacts on the market)

Request Report Sample
Inquiry Before Buying



Frequently Asked Questions (FAQs):
A. Yes, we provide customization with every report to fulfill your market research requirement.
A. No, generally we don’t charge for report customization.
A. Yes, we will add the more coutries analysis in the report, please mention the countries you are looking.
A. Yes, we provide research support for all our clients to resolve their issue regarding the report.
A. Yes, you can purchase only a regional or a country market report with our best price which is less than the global report.
A. Yes, we provide a better discount for startups and individuals.
A. Our database consists of over 70,000 market research reports; if still not available on the website, feel free to write us. Our team will be happy to assist you in the same. Let us know if you are looking for the dataset.
(For more information, feel free to write us at sales@researchcorridor.com)
Select License Type
$3200/- Single User License
$4800/- Multi User License
$6400/- Corporate License

Paypal Certified Payment
Why To Choose Us:
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client are returning clients
  • 100,000+ data points in our comprehensive database
  • 24x5 availability - we are always there when you need us
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report

Impacts of COVID-19
COVID-19 Impact on the Epoprostenol Market

For Any Assitance

Call Us: +1 520-686-7060
Email: sales@researchcorridor.com

Our Clients